Evidence map›Paper›PMID 39518123›Full record

ReviewCancers2024

Deciphering the Tumor Microenvironment in Prostate Cancer: A Focus on the Stromal Component.

Hubert Pakula, Filippo Pederzoli, Giuseppe Nicolò Fanelli, Pier Vitale Nuzzo, Silvia Rodrigues, Massimo Loda

Abstract readReview
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. A Metastasis-competent CAF Subpopulation Defined byRecent patents on anti-cancer drug discovery · 2026
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hubert PakulaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0003-0070-3913
Filippo PederzoliDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0003-3873-7465
Giuseppe Nicolò FanelliDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0001-7069-7980
Pier Vitale NuzzoDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-5618-8079
Silvia RodriguesDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-7239-8324
Massimo LodaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0001-9674-8379

Funding

Project 3: Analysis of intrinsic and extrinsic factors that promote prostate neuroendocrine differentiationP01CA265768 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MICHAEL M. SHEN · 2022 to 2026
$13.4M
Weill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI RICKMAN, DAVID S. · 2017 to 2021
$10.9M
Preclinical analyses of advanced prostate cancer in genetically-engineered miceR01CA173481 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Cory Abate-Shen · 2013 to 2026
$6.1M
Molecular mechanisms of prostate cancer metastasisR01CA183929 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABATE-SHEN, CORY · 2015 to 2025
$4.1M
Hardwiring Mechanism into Predicting Cancer Phenotypes by Computational LearningR01CA200859 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARCHIONNI, LUIGI · 2016 to 2020
$1.9M
Next-Gen Oncopathology ProgramT32CA260293 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Ethel Cesarman, BENJAMIN MONTEVERDE KLEAVELAND · 2022 to 2026
$1.4M
NCI NIH HHS P01 CA265768NCI NIH HHS P50 CA211024NCI NIH HHS R01 CA173481NCI NIH HHS R01 CA183929NCI NIH HHS R01 CA200859NCI NIH HHS T32 CA260293
6 · The paper itself

Abstract

Prostate cancer progression is significantly affected by its tumor microenvironment, in which mesenchymal cells play a crucial role. Stromal cells are modified by cancer mutations, response to androgens, and lineage plasticity, and in turn, engage with epithelial tumor cells via a complex array of signaling pathways and ligand-receptor interactions, ultimately affecting tumor growth, immune interaction, and response to therapy. The metabolic rewiring and interplay in the microenvironment play an additional role in affecting the growth and progression of prostate cancer. Finally, therapeutic strategies and novel clinical trials with agents that target the stromal microenvironment or disrupt the interaction between cellular compartments are described. This review underscores cancer-associated fibroblasts as essential contributors to prostate cancer biology, emphasizing their potential as prognostic indicators and therapeutic targets.

Indexed as

cancer-associated fibroblasts (CAFs)castration-resistant prostate cancer (CRPC)mesenchymal cellsprostate cancer (PCa)tumor microenvironment (TME)

Identifiers

PMID39518123
PMCPMC11544791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.